Literature DB >> 9419063

End of life decisions in amyotrophic lateral sclerosis: a cross-cultural perspective.

A Smyth1, M Riedl, R Kimura, R Olick, M Siegler.   

Abstract

In an era where life-sustaining technology offers physicians unprecedented powers to prolong survival in terminal illness, the question of how end of life decisions are made has become a major subject of study and debate. Amyotrophic lateral sclerosis (ALS) is a disease in which physical ability declines while mental capacity most often remains intact. Since most patients with ALS die of respiratory failure, a distinguishing feature of this disease is whether a patient is offered and accepts a chance to go on long-term mechanical ventilation. This unusual feature makes ALS a compelling model for studying end of life decisions in different countries. This paper reviews the literature and presents preliminary data on how end of life decisions in ALS are made in the US, Great Britain, and Japan. We address this issue by examining how cultural differences in truth-telling and informed consent, societal differences in attitudes toward the use of artificial life support, and legal differences in the role and status of advance directives in each country influenced decisions in the following three groups of patients: (1) the mentally competent; (2) mentally incompetent patients who previously completed advance directives when competent; and (3) mentally incompetent patients who have not provided advance guidance about their wishes.

Entities:  

Mesh:

Year:  1997        PMID: 9419063     DOI: 10.1016/s0022-510x(97)00253-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  What would brain-computer interface users want? Opinions and priorities of potential users with amyotrophic lateral sclerosis.

Authors:  Jane E Huggins; Patricia A Wren; Kirsten L Gruis
Journal:  Amyotroph Lateral Scler       Date:  2011-05-02

2.  Therapeutic decisions in ALS patients: cross-cultural differences and clinical implications.

Authors:  Peter M Andersen; Magdalena Kuzma-Kozakiewicz; Jürgen Keller; Helena E A Aho-Oezhan; Katarzyna Ciecwierska; Natalia Szejko; Cynthia Vázquez; Sarah Böhm; Gisela Badura-Lotter; Thomas Meyer; Susanne Petri; Katharina Linse; Andreas Hermann; Olof Semb; Erica Stenberg; Simona Nackberg; Johannes Dorst; Ingo Uttner; Ann-Cristin Häggström; Albert C Ludolph; Dorothée Lulé
Journal:  J Neurol       Date:  2018-05-04       Impact factor: 4.849

3.  Duration of prion disease is longer in Japan than in other countries.

Authors:  Kiwamu Nagoshi; Atsuko Sadakane; Yosikazu Nakamura; Masahito Yamada; Hidehiro Mizusawa
Journal:  J Epidemiol       Date:  2011-05-28       Impact factor: 3.211

4.  What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives.

Authors:  Anne Hogden; David Greenfield; Peter Nugus; Matthew C Kiernan
Journal:  Patient Prefer Adherence       Date:  2012-11-27       Impact factor: 2.711

5.  Chinese specific characteristics of sporadic Creutzfeldt-Jakob disease: a retrospective analysis of 57 cases.

Authors:  Wei Zhao; Jia-Tang Zhang; Xiao-Wei Xing; De-Hui Huang; Cheng-Lin Tian; Wei-Quan Jia; Xu-Sheng Huang; Wei-Ping Wu; Chuan-Qiang Pu; Sen-Yang Lang; Sheng-Yuan Yu
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

6.  Analysis of Chinese patients with sporadic Creutzfeldt-Jakob disease.

Authors:  Jing Yang; Haiyan Kuang; Qiong Wang; Jiao Liu; Xueping Chen; Huifang Shang
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.